Seeking Alpha

More on Bristol-Myers (BMY -1.6%) Q1: net profit -45% to $609M, with earnings hurt by patent...

More on Bristol-Myers (BMY -1.6%) Q1: net profit -45% to $609M, with earnings hurt by patent expirations for Plavix and Avapro/Avalide. Excluding those drugs, net sales +10%. Sales breakdown: Orencia (rheumatoid arthritis) +26%, Yervoy (melanoma) +49%, Sprycel (leukemia) +24%, Onglyza (Type 2 diabetes) +25% and Baraclude (hepatitis B) +13%. Confirms 2013 adjusted EPS guidance of $1.78-$1.88 vs consensus of $1.83. (PR)
Comments (1)
  • cyrano13
    , contributor
    Comments (106) | Send Message
     
    The evergreening prohibition is spreading worldwide. This will hit all US big pharma gradually, but significantly.
    25 Apr 2013, 11:53 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|